Welcome to our dedicated page for Senti Bioscience news (Ticker: SNTI), a resource for investors and traders seeking the latest updates and insights on Senti Bioscience stock.
Overview
Senti Biosciences (SNTI) is a clinical-stage biotechnology company that harnesses the power of synthetic biology to develop advanced cell and gene therapies. With a focus on oncology and other unmet medical needs, the company has pioneered a proprietary Gene Circuit platform designed to program off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells. This cutting-edge technology enables precise targeting of cancer cells while sparing healthy cells, potentially offering a transformative approach to treating diseases with limited therapeutic options.
Technology and Innovation
Senti Biosciences stands out with its innovative use of Gene Circuits, a technology that integrates synthetic biology and advanced gene editing techniques. By incorporating logic gates (such as OR and NOT mechanisms) into the design of CAR-NK cells, the company is able to finely tune therapeutic activity. This intelligent system enhances the specificity of cell therapies, ensuring that cancer cells are eliminated while preserving essential healthy tissues.
Therapeutic Platforms
The company’s pipeline comprises wholly-owned programs that utilize off-the-shelf CAR-NK cells engineered via its Gene Circuit platform. Among these, its product candidates are designed to address significant challenges in both liquid and solid tumors. The adaptive nature of the platform allows for tailored approaches in treating hematologic malignancies like acute myeloid leukemia (AML) and solid tumors such as hepatocellular carcinoma (HCC). Through rigorous preclinical studies, the potential of these therapies has been demonstrated by their selective cytotoxic effects and improved control over therapeutic payload expression.
Clinical Development and Strategic Collaborations
Senti Biosciences is advancing multiple clinical programs that highlight its commitment to innovation in cell therapy. Its clinical-stage trials are designed to evaluate the safety, tolerability, and initial efficacy of its gene circuit-enabled therapies. In parallel, the company has established strategic collaborations with other biotechnology firms and research institutions to accelerate clinical development and expand its technological capabilities. These alliances not only foster shared expertise but also enhance the scalability and robustness of its therapeutic design platform.
Market Position and Value Proposition
Positioned at the intersection of synthetic biology and immunotherapy, Senti Biosciences is addressing critical limitations of conventional cancer treatments. By leveraging a proprietary platform that offers enhanced precision, safety, and adaptability, the company is poised to impact the field of cell and gene therapy in a significant manner. Its focus on developing off-the-shelf therapies aims to streamline manufacturing processes and reduce variability, thereby offering potential operational advantages in the competitive biotechnology landscape.
Scientific Expertise and Research Acumen
The company is driven by a multidisciplinary team of engineers, scientists, and entrepreneurs who bring a wealth of experience in synthetic biology, gene editing, and clinical research. This blend of expertise underpins the rigorous development process and enables Senti Biosciences to tackle complex therapeutic challenges with scientific rigor. The integration of industry-specific terminology and methods in its research demonstrates a high level of authority and trustworthiness in the rapidly evolving field of biopharmaceuticals.
Commitment to Quality and Safety
In every stage of its research and development, Senti Biosciences adheres to stringent quality and regulatory standards. The design of its Gene Circuit technology is tailored not only to enhance therapeutic efficacy but also to significantly reduce potential off-target effects. This careful balance of innovation and safety is central to the company’s commitment to improving patient outcomes, particularly for those with incurable diseases.
Conclusion
Through its groundbreaking work in synthetic biology and advanced cell therapy, Senti Biosciences exemplifies a modern approach to combating cancer and other severe diseases. By focusing on a versatile and scalable platform, the company continues to build its reputation as a trusted innovator in the biotechnology space. Its comprehensive strategy—encompassing technology development, strategic collaborations, and rigorous clinical evaluation—positions it as a vital contributor to the evolution of precision medicine.
Senti Biosciences (NASDAQ: SNTI) announced three abstract presentations at the upcoming AACR Annual Meeting 2025 (April 25-30, Chicago), showcasing new data from their lead product SENTI-202, a CAR NK cell therapy for relapsed/refractory acute myeloid leukemia (r/r AML).
The presentations include an oral minisymposium on clinical data, and two poster sessions focusing on correlative data and preclinical characterization of their Logic Gate technology. The preclinical data demonstrates that EMCN inhibitory CAR (NOT gate) effectively protects healthy bone marrow cells from on-target off-tumor toxicity in vivo.
Dr. Kanya Rajangam, President, Head of R&D and Chief Medical Officer, emphasized the potential of SENTI-202 for treating r/r AML and highlighted the broader applications of Logic Gating technology in oncology for selective cancer targeting while preserving healthy cells.
Senti Biosciences (NASDAQ: SNTI) has reported its Q4 and full-year 2024 financial results, highlighting significant clinical progress and financial developments. The company's lead product SENTI-202 showed promising initial Phase 1 results, with 2 out of 3 relapsed/refractory AML patients achieving MRD negative complete remission at the lowest dose level, maintaining remission as of March 2025.
The company substantially strengthened its financial position through a $47.6 million PIPE financing led by Celadon Partners, with participation from notable investors. The net proceeds of $45.1 million are expected to extend the company's runway into 2026. Additionally, Senti Bio received $1.5 million from CIRM, bringing total grant funding to $6.4 million.
Financial results show cash and cash equivalents of $48.3 million as of December 31, 2024. Q4 R&D expenses decreased to $7.8 million from $9.1 million year-over-year, while G&A expenses reduced to $8.4 million from $9.3 million. The company reported a Q4 net loss of $0.6 million ($0.67 per share) and a full-year 2024 net loss of $52.8 million ($12.03 per share).
Senti Biosciences (NASDAQ: SNTI) has appointed Feng Hsiung to its Board of Directors, effective March 7, 2025. Hsiung, who brings extensive business, finance, and investment expertise, will serve on the Board's Audit Committee. He is currently the Founder, Chief Investment Officer, and CEO of Acion Partners, which has a strategic partnership with KKR.
Additionally, the company granted stock options to three new employees, including 174,200 options to new CFO Jay Cross, with a per share exercise price of $3.52. The total grant comprises 202,700 shares under the company's 2022 Inducement Equity Plan, approved in accordance with NASDAQ Listing Rule 5635(c)(4).
Senti Biosciences (SNTI) has expanded its leadership team with two strategic appointments. Jay Cross will join as Chief Financial Officer on March 3, 2025, overseeing financial strategy, operations, and investor relations. Faraz Siddiqui joined in January 2025 as Senior Vice President of Technical Operations, managing process development, manufacturing, and supply chain.
CEO Timothy Lu expressed confidence that Cross's financial expertise and Siddiqui's technical operations leadership will support the company's clinical pipeline advancement, particularly for SENTI-202 and SENTI-301A. Cross brings extensive experience from Sonnet BioTherapeutics, where he led a capital campaign raising over $100 million, and from 20 years on Wall Street at firms including Chardan, SAC Capital, and Goldman Sachs.
Siddiqui contributes 27 years of biopharmaceutical experience, particularly in cell therapies, from previous roles at IGM Biosciences, Instil Bio, Kite Pharma, and Genentech, where he specialized in process development and manufacturing operations.
Senti Biosciences (NASDAQ: SNTI) has secured an additional $11.5 million in financing, comprising a $10 million private placement equity investment from Celadon Partners and $1.5 million from a CIRM grant. This additional funding brings the total PIPE financing round to $47.6 million, with participation from notable investors including NEA, Leaps by Bayer, and Nantahala Capital.
The company plans to use the proceeds to fund the development of its SENTI-202 program, manufacturing scale-up, research activities, and general corporate purposes. The funding has extended the company's cash runway guidance into 2026. The CIRM grant payment brings the total received from this source to $6.4 million out of the $8 million total grant announced in June 2024.
Senti Biosciences (SNTI) announced the first patient dosing in a clinical trial of SN301A for hepatocellular carcinoma (HCC) in mainland China, in collaboration with Celest Therapeutics. The trial aims to evaluate safety, pharmacokinetics, and preliminary anti-tumor activity of SN301A, a CAR-NK cell therapy utilizing Senti's Gene Circuit platform, in patients with advanced GPC3-expressing HCC across multiple dose cohorts.
Celest is leading the clinical development, operations, and manufacturing in China, with Senti Bio providing technical and strategic input. The study will assess adverse events, dose-limiting toxicities, and efficacy using standard liver cancer response criteria. The collaboration may expand to Hong Kong, Macau, and Taiwan, while Senti Bio retains rights outside these regions.
Senti Biosciences (Nasdaq: SNTI) has announced new employment inducement grants approved by its Compensation Committee on November 26, 2024. The committee granted stock options to three new employees to purchase a total of 49,778 shares of company common stock at an exercise price of $2.11 per share. These grants were made under the company's 2022 Inducement Equity Plan, which was adopted on August 5, 2022, and are in accordance with NASDAQ Listing Rule 5635(c)(4) as inducement material for new employees joining the company.
Senti Biosciences (Nasdaq: SNTI) has secured a $37.6 million private placement financing through the sale of 16,713 shares of Series A Convertible Preferred Stock. The PIPE financing, led by Celadon Partners with participation from NEA, Leaps by Bayer, and others, is expected to close by December 5, 2024. Investors will receive warrants to purchase up to 25,069,500 common stock shares, subject to stockholder approval. An additional option for $10 million in Preferred Stock was granted to one investor. The proceeds will fund the SENTI-202 program development, manufacturing scale-up, and general corporate purposes.
Senti Biosciences (NASDAQ: SNTI) reported positive initial clinical data from Phase 1 trial of SENTI-202, a Logic Gated CAR-NK cell therapy for relapsed/refractory hematologic malignancies including AML. Two out of three patients achieved MRD negative complete remission at the lowest dose level (1.0 billion CAR+ NK cells per dose). Both patients maintain remission after 4+ and 3+ months respectively. The therapy was generally well-tolerated with no dose limiting toxicities. SENTI-202 is designed to selectively target CD33 and/or FLT3-expressing malignancies while sparing healthy bone marrow cells. The trial continues with dose escalation, and additional response and durability data are expected in 2025.
Senti Biosciences (NASDAQ: SNTI) has appointed Fran Schulz to its Board of Directors and as chairperson of the Board's Audit Committee. Schulz, a founding member of Ernst & Young's Life Sciences Practice, brings over 35 years of experience and has been involved in over 100 equity and debt transactions totaling more than $15 billion. She has extensive expertise in finance, strategic planning, and corporate transactions in the life sciences industry. The appointment coincides with Dr. Omid Farokhzad's departure from the Board. Schulz currently serves on the boards of EDAP TMS SA and Menlo College as Audit Committee Chair.
FAQ
What is the current stock price of Senti Bioscience (SNTI)?
What is the market cap of Senti Bioscience (SNTI)?
What is the core focus of Senti Biosciences?
How does the Gene Circuit platform work?
What types of diseases does Senti Biosciences target?
What makes Senti Biosciences' approach unique in the biotechnology space?
What are CAR-NK cells and why are they important?
How does Senti Biosciences ensure safety in its therapies?
What role do strategic collaborations play at Senti Biosciences?
How does Senti Biosciences position itself in the competitive market?
